Welcome to our dedicated page for Park Hotels & Resorts SEC filings (Ticker: PK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Park Hotels & Resorts� filings are more than numbers—they map the pulse of 28 upper-upscale and luxury hotels spread across gateway cities and iconic resorts. Whether you are dissecting RevPAR sensitivity or gauging renovation spending, the annual report 10-K details every property lease, tax shield, and depreciation schedule. Our platform delivers the Park Hotels & Resorts annual report 10-K simplified so you can spot FFO drivers in minutes instead of hours.
Need timely updates? We stream Park Hotels & Resorts quarterly earnings report 10-Q filing alerts the moment they hit EDGAR, accompanied by AI-powered summaries that translate legalese into clear occupancy, ADR, and segment margin trends. Material announcements often surface first in an 8-K; our dashboard tags each Park Hotels & Resorts 8-K material events explained entry with plain-language context, helping you connect headline moves to dividend outlook.
Tracking managers� confidence is easier too. Follow Park Hotels & Resorts insider trading Form 4 transactions and Park Hotels & Resorts Form 4 insider transactions real-time to monitor executive stock dealings around capital recycling news. Curious about pay structure? The latest Park Hotels & Resorts proxy statement executive compensation breaks down incentive metrics, while our AI highlights any shifts tied to RevPAR recovery. From Park Hotels & Resorts earnings report filing analysis to understanding Park Hotels & Resorts SEC documents with AI, Stock Titan unifies every disclosure type�10-K, 10-Q, 8-K, S-3, and more—into one searchable hub. Make informed calls on dividend stability, asset dispositions, or Park Hotels & Resorts executive stock transactions Form 4 patterns without wading through hundreds of pages.
Flora Growth Corp. (FLGC) Q2-25 10-Q highlights:
- Revenue: $14.8 m, -5.7 % YoY; H1-25 $26.6 m, -21 % YoY.
- Gross profit: $2.8 m (19.1 % margin) vs $3.2 m prior year.
- Net loss: Q2 -$2.4 m (-$0.11 EPS) vs -$2.7 m (-$0.21 EPS); H1 -$3.2 m vs -$6.0 m.
- Cash: $1.5 m, down from $6.0 m at 12-31-24; digital assets added ($1.1 m).
- Total assets: $22.7 m (-14 % YTD); current liabilities $13.8 m > current assets $13.2 m.
- Shareholders� equity: $4.0 m vs $4.5 m YE-24.
- Going concern: substantial doubt; company evaluating cost cuts & new financing.
- Capital actions: May �25 private placement raised $1.2 m; 726,992 pre-funded warrants issued. 1-for-39 reverse split to cure Nasdaq bid-price deficiency effective 4-Aug-25.
- M&A: Acquired United Beverage Distribution (2-Feb-25) for $2.9 m (cash $0.5 m, stock $0.8 m, notes $2.1 m); goodwill +$2.4 m.
- Deconsolidation: Insolvent European/Canadian subsidiaries removed, recording $1.2 m gain and reducing contingencies.
- Debt: �2.3 m German credit lines (4.8-5.2 %); $2.2 m promissory notes to United sellers (6 %).
- Legal & tax contingencies: $3.2 m provisions (sales tax & lease dispute); additional lawsuit over JustCBD earn-out could add 0.63 m shares.
Key messages: while losses are narrowing and liabilities decreased, liquidity is tight, cash runway limited, and compliance with Nasdaq listing rules depends on the forthcoming reverse split.
On July 31, 2025, Cloudflare, Inc. (NYSE: NET) filed a Form 8-K to furnish its fiscal second-quarter results for the period ended June 30, 2025. The document contains no financial figures; instead, it directs investors to (i) a detailed press release attached as Exhibit 99.1 and (ii) supplemental materials posted on the company’s investor-relations website. Disclosure is made under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD). The company reiterates that the information is considered “furnished,� not “filed,� thereby limiting Section 18 liability and preventing automatic incorporation into other SEC documents. No other material events, transactions, or guidance updates are noted.
Medicus Pharma Ltd. (NASDAQ: MDCX) filed Prospectus Supplement No. 3 to register 2.26 million common shares issuable from outstanding public warrants (exercise price $4.64; expiry Nov 15 2029). The supplement incorporates an accompanying Current Report detailing the issuance of a $2.5 million third debenture to YA II PN, Ltd. (Yorkville) on June 17 2025, the final tranche under a previously disclosed $5 million secured debenture facility.
Key terms of the Yorkville financing
- Total debenture principal issued to date: $5 million (three tranches of $1.25 m, $1.25 m and $2.5 m)
- Aggregate net proceeds received: $4.5 million after original-issue discounts
- Coupon: 8.0% annual; increases to 18.0% upon default
- Maturity: February 2 2026; guaranteed by all subsidiaries via a global guaranty
The transaction strengthens near-term liquidity but layers additional secured debt on the balance sheet and introduces accelerated interest-rate risk in the event of default. The warrants remain out-of-the-money (share price $2.58 vs. strike $4.64), limiting immediate dilution yet signaling potential future share issuance if the stock appreciates.
Investors should weigh the improved cash position against a compressed maturity schedule, 8% fixed interest expense, and a possible 18% penalty rate, as well as eventual equity dilution from both the debenture terms (if convertible) and registered warrants.
Timothy J. Naughton, Director of Park Hotels & Resorts, reported acquiring 2,484 shares of unrestricted common stock on June 23, 2025. This transaction was made under the company's 2017 Stock Plan for Non-Employee Directors, where Naughton elected to receive stock in lieu of cash fees for his Q2 2025 board service.
Key transaction details:
- Shares were granted at $0 cost and vested immediately
- The stock value was based on NYSE closing price on grant date
- Following the transaction, Naughton directly owns 138,422 shares
- Transaction was filed via Form 4 on June 28, 2025
This insider transaction represents standard board compensation practice where directors can choose to receive equity instead of cash compensation, demonstrating alignment with shareholder interests.
Park Hotels & Resorts director Patricia M. Bedient received an equity grant of 2,743 shares of unrestricted common stock on June 23, 2025, as compensation for Q2 2025 board service. The shares were granted under the company's 2017 Stock Plan for Non-Employee Directors and vested immediately upon issuance.
Key details of the transaction:
- Transaction was made at $0 cost to the director
- Shares were issued in lieu of cash board fees
- Share value was based on NYSE closing price on grant date
- Following the transaction, Bedient owns 134,215 shares directly
This Form 4 filing represents standard board compensation practice and demonstrates alignment between director and shareholder interests through equity-based compensation.
Park Hotels & Resorts Director Christie B. Kelly reported acquiring 2,865 shares of unrestricted common stock on June 23, 2025, as compensation for board service during Q2 2025. The shares were granted under the company's 2017 Stock Plan for Non-Employee Directors and vested immediately upon issuance.
Key details of the transaction:
- Transaction was executed at $0 cost to the director
- Shares were issued in lieu of cash fees for board service
- Share value was based on NYSE closing price on grant date
- Following the transaction, Kelly owns 142,127 shares directly
- Grant occurred 5 business days before regular fee payment date
This Form 4 filing represents standard board compensation practice where directors elect to receive equity instead of cash payments, demonstrating alignment with shareholder interests.
Park Hotels & Resorts Director Stephen I. Sadove received 3,513 shares of unrestricted common stock on June 23, 2025, as compensation for Q2 2025 board service in lieu of cash fees. The shares were granted under the company's 2017 Stock Plan for Non-Employee Directors and vested immediately upon issuance.
Following the transaction, Sadove's beneficial ownership consists of:
- 87,832 shares held directly
- 20,000 shares held indirectly through the Sadove Family Delaware Dynasty Trust
- 23,816 shares held indirectly through the Stephen I. Sadove Revocable Trust
The stock award was valued based on the NYSE closing price on the grant date. The transaction was reported via Form 4 filing on June 25, 2025, within the required reporting timeline.